Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study
Introduction: Medical care and surveillance of inflammatory bowel disease (IBD) patients have been shown to be far from satisfactory. Data on therapy patterns and surveillance measures in IBD patients are scarce. We, therefore, aimed to compare the therapy patterns and surveillance management of IBD...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2022-04-01
|
| Series: | Inflammatory Intestinal Diseases |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/524741 |
| _version_ | 1818252466128420864 |
|---|---|
| author | Caroline Bähler Beat Brüngger Eva Blozik Stephan R. Vavricka Alain M. Schoepfer |
| author_facet | Caroline Bähler Beat Brüngger Eva Blozik Stephan R. Vavricka Alain M. Schoepfer |
| author_sort | Caroline Bähler |
| collection | DOAJ |
| description | Introduction: Medical care and surveillance of inflammatory bowel disease (IBD) patients have been shown to be far from satisfactory. Data on therapy patterns and surveillance measures in IBD patients are scarce. We, therefore, aimed to compare the therapy patterns and surveillance management of IBD patients in the year before and after IBD-related hospitalization. Methods: We examined medical therapy, surveillance management (influenza vaccination, dermatologist visits, Pap smear screening, creatinine measurements, iron measurements, and ophthalmologist visits) and healthcare utilization in 214 ulcerative colitis (UC) and 259 Crohn’s disease (CD) patients who underwent IBD-related hospitalization from 2012 to 2014. Results: IBD-related drug classes changed in 64.5% of IBD patients following hospitalization. During the 1-year follow-up period, biological treatment increased in UC and CD patients, while steroid use decreased. Following hospitalization, 63.1% of UC and 27.0% of CD patients received 5-ASA. Only 21.6% of all IBD patients had a flu shot, and 19.6% of immunosuppressed IBD patients were seen by a dermatologist in the follow-up; other surveillance measures were more frequent. Surveillance before hospital admission and consultations by gastroenterologists were strongly correlated with surveillance during the postoperative follow-up, while gender and diagnosis (UC vs. CD) were not. During the 1-year follow-up, 20.5% of all IBD patients had no diagnostic or disease-monitoring procedure. Discussion/Conclusion: Surveillance measures for IBD patients are underused in Switzerland. Further research is needed to examine the impact of annual screenings and surveillance on patient outcomes. |
| first_indexed | 2024-12-12T16:24:37Z |
| format | Article |
| id | doaj.art-d8052e92a547443da53b9e68ea57969e |
| institution | Directory Open Access Journal |
| issn | 2296-9403 2296-9365 |
| language | English |
| last_indexed | 2024-12-12T16:24:37Z |
| publishDate | 2022-04-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Inflammatory Intestinal Diseases |
| spelling | doaj.art-d8052e92a547443da53b9e68ea57969e2022-12-22T00:18:55ZengKarger PublishersInflammatory Intestinal Diseases2296-94032296-93652022-04-0111410.1159/000524741524741Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort StudyCaroline Bähler0https://orcid.org/0000-0002-4650-1463Beat Brüngger1https://orcid.org/0000-0001-6173-5375Eva Blozik2Stephan R. Vavricka3Alain M. Schoepfer4Department of Health Sciences, Helsana Insurance Group, Zurich, SwitzerlandDepartment of Health Sciences, Helsana Insurance Group, Zurich, SwitzerlandDepartment of Health Sciences, Helsana Insurance Group, Zurich, SwitzerlandCenter for Gastroenterology and Hepatology, Zurich, SwitzerlandDivision of Gastroenterology and Hepatology, Centre Hospitalier Universitaire, Vaudois/CHUV and University of Lausanne, Lausanne, SwitzerlandIntroduction: Medical care and surveillance of inflammatory bowel disease (IBD) patients have been shown to be far from satisfactory. Data on therapy patterns and surveillance measures in IBD patients are scarce. We, therefore, aimed to compare the therapy patterns and surveillance management of IBD patients in the year before and after IBD-related hospitalization. Methods: We examined medical therapy, surveillance management (influenza vaccination, dermatologist visits, Pap smear screening, creatinine measurements, iron measurements, and ophthalmologist visits) and healthcare utilization in 214 ulcerative colitis (UC) and 259 Crohn’s disease (CD) patients who underwent IBD-related hospitalization from 2012 to 2014. Results: IBD-related drug classes changed in 64.5% of IBD patients following hospitalization. During the 1-year follow-up period, biological treatment increased in UC and CD patients, while steroid use decreased. Following hospitalization, 63.1% of UC and 27.0% of CD patients received 5-ASA. Only 21.6% of all IBD patients had a flu shot, and 19.6% of immunosuppressed IBD patients were seen by a dermatologist in the follow-up; other surveillance measures were more frequent. Surveillance before hospital admission and consultations by gastroenterologists were strongly correlated with surveillance during the postoperative follow-up, while gender and diagnosis (UC vs. CD) were not. During the 1-year follow-up, 20.5% of all IBD patients had no diagnostic or disease-monitoring procedure. Discussion/Conclusion: Surveillance measures for IBD patients are underused in Switzerland. Further research is needed to examine the impact of annual screenings and surveillance on patient outcomes.https://www.karger.com/Article/FullText/524741surveillancehealthcare utilizationbiologicsinflammatory bowel disease |
| spellingShingle | Caroline Bähler Beat Brüngger Eva Blozik Stephan R. Vavricka Alain M. Schoepfer Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study Inflammatory Intestinal Diseases surveillance healthcare utilization biologics inflammatory bowel disease |
| title | Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study |
| title_full | Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study |
| title_fullStr | Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study |
| title_full_unstemmed | Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study |
| title_short | Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study |
| title_sort | therapy patterns and surveillance measures of inflammatory bowel disease patients beyond disease related hospitalization a claims based cohort study |
| topic | surveillance healthcare utilization biologics inflammatory bowel disease |
| url | https://www.karger.com/Article/FullText/524741 |
| work_keys_str_mv | AT carolinebahler therapypatternsandsurveillancemeasuresofinflammatoryboweldiseasepatientsbeyonddiseaserelatedhospitalizationaclaimsbasedcohortstudy AT beatbrungger therapypatternsandsurveillancemeasuresofinflammatoryboweldiseasepatientsbeyonddiseaserelatedhospitalizationaclaimsbasedcohortstudy AT evablozik therapypatternsandsurveillancemeasuresofinflammatoryboweldiseasepatientsbeyonddiseaserelatedhospitalizationaclaimsbasedcohortstudy AT stephanrvavricka therapypatternsandsurveillancemeasuresofinflammatoryboweldiseasepatientsbeyonddiseaserelatedhospitalizationaclaimsbasedcohortstudy AT alainmschoepfer therapypatternsandsurveillancemeasuresofinflammatoryboweldiseasepatientsbeyonddiseaserelatedhospitalizationaclaimsbasedcohortstudy |